The use of cannabis to treat the symptoms of cancer and associated treatments is well known, but a growing body of evidence shows how cannabis can also be used as a direct anticancer agent. In this presentation, preclinical studies showing the anticancer effects of specific cannabinoids will be discussed, along with human reports of remissions from aggressive cancers after using high doses of cannabinoids.

Learning Objectives:

1. Describe the basic biological mechanisms by which cannabinoids have been shown to inhibit cancers
2. Understand the human and clinical evidence demonstrating how preclinical effects are translating to humans

Dr. Sulak will review the evidence supporting the use of cannabis to not only treat serious disease, but to prevent them and maintain health, with practical and easy to implement dosing strategies. This lecture will also cover non-cannabis influences on our endocannabinoid physiology and focus on chronic conditions including sleep disorders, cardiovascular disease, neurologic injury, obesity and diabetes, and more.

Imagine the need for agriculture being removed completely from the cannabis supply chain.

Cellibre’s vision is to leverage biology to make products more sustainable, efficiently and reliably across industries by employing the multidisciplinary science known as cellular agriculture. We leverage our expertise in cellular agriculture to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale.

Cells are inherently superior producers of products for a variety of reasons. First, nature’s machinery can conduct complex reactions at nanoscale precision that are difficult and, in some cases, impossible to achieve by any other means. This ability leads to improved quality and consistency over many legacy manufacturing processes and enable the potential to develop completely novel products. Next, cells copy themselves through cellular division which serves to multiple their natural brick and mortar infrastructure, often with minimal nutrients. This means that production scales itself. In addition, cells repair themselves. Cells have natural machinery that reacts when cell production is impaired to repair the damaged parts and return to regular course. This translates into lower maintenance costs and less downtime. Lastly, cell-based production is uniquely sustainable. Cells very efficiently convert inputs, typically low cost media, into high-value products. In addition, byproducts created as a resulted of bioproduction are generally non-toxic because harmful substances would terminate the cells and stop production of all materials, including the toxins themselves.

Cellibre's strategic focus is deploying its expertise in cellular agriculture to revolutionize the way cannabis extracts and cannabinoid-based medicines are sourced, produced and consumed. The resultant outputs from the bio-based manufacture of any cannabinoid (including minor cannabinoids) will be high-quality, sustainable and specific cannabinoids for use across applications. The significant deficiencies throughout the current cannabinoid supply chain, the resource requirements in the agricultural process and the evolving regulatory environment globally provide Cellibre an immense opportunity to disrupt a $50+ billion market via the production of high-quality, sustainable, specific and pure, medical-grade natural products.

Learning Objectives:

1. What is cellular agriculture and the science of synthetic biology
2. Why is fermentation an advantaged method for the production of cannabis extracts on virtually all metrics

The cannabis industry has realized that not just one or two compounds of the plant are important for a variety of medical indications. A plethora of metabolites, e.g. terpenes, flavonoids and cannabinoids, give rise to the desired effects. Such chemical makeups are not only dictated by the strain/cultivar, but also influenced by grow methods, drying and curing, and also the extraction method. Unfortunately, it is mostly overlooked how these processes lead to high quality, reliable products. This talk will discuss our latest findings on how to control the molecular makeup throughout the production pipeline.

Learning Objectives:

1. The audience will learn about the changes that happen to cannabis and its bioactive molecules during different production stages.
2. The audience will learn about ways of how to control such changes and even consciously manipulate molecular profiles.

With the legalization process currently taking place in the US, finding new techniques for the fast, cheap, and comprehensive analysis of Cannabis sativa components has become a major point of interest. Different analytical tools have been widely used for the characterization of the main components of the plant, cannabinoids and terpenes. Both these classes of compounds can be analyzed with the use of the gas chromatograph coupled with the mass spectrometer (GC-MS), and with the vacuum ultraviolet detector (GC-VUV).

In this research, we used these two technologies to analyze cannabinoids and terpenes found in C. sativa; the sensitivity of the multiple reaction monitoring (MRM) mode used in the GC-MS allowed for the analysis of impurities, while the GC-VUV was more adapt for a potency testing. Terpenes were analyzed on GC-VUV due to the possibility of the instrument to differentiate between isobaric compounds, and to deconvolve coeluting peaks that otherwise would need a longer chromatographic separation.

Learning Objectives:

1. Why GC is a necessary tool for R&D and QC labs in the Cannabis world.
2. How new technologies are advancing to give a more comprehensive understanding of the plant.

It can often be a very challenging task to understand what rules and regulations you are responsible for in a cannabis business. Being out of compliance can be a costly mistake with huge fines or even a loss of licensure at stake. Learn about what resources are available for people just like yourself that can help you save time, money, and sleep better at night.

Todays drug programs in schools use abstinence based approaches that are centered around the idea that avoiding marijuana is the only acceptable option and often rely on the stigmatization of drug use and users. Although there are many reasons why youth may use cannabis, cannabis education has framed use in very narrow ways and ignored the diverse spectrum of use patterns. Youth often get much of their information online, and many older programs have ignored the digital context of how our generation obtains, explores, and generates information about marijuana use. Education must provide honest, age-appropriate information, which will ultimately arm young people with the skills necessary to take personal responsibility for their health and decision making. Youth will encounter cannabis, so honest information and ongoing discussions about cannabis will help them navigate the changing legal landscape and experiences with friends, family and acquaintances.

Learning Objectives:

1. Heavy handed and fear based approaches to drug education can alienate young people and undermine the credibility of the education efforts.
2. Emerging research suggests the importance of including harm reduction strategies in drug education to address the needs of young people, including those who may be using cannabis.

If your lab has decided to apply for ISO/IEC 17025 accreditation as your state requires it or to demonstrate the reliability of your lab results to potential customers, you may think what next? Achieving and maintaining the necessary compliance such as ISO 17025:2017 accreditation is a time-consuming, costly, and complicated process. It includes managing and tracking employee training and competency, Standard Operating Protocol (SOP's) management, risk management, and instrument maintenance and calibration. An informatics solution such as Laboratory Information Management System (LIMS) can make this job much easier.

1. ISO 17025 Certification helps cannabis testing labs to prove their technical capabilities, strong commitment to quality, operational efficiency and management practices. The presentation will highlight both the management and technical requirements that a cannabis testing laboratory should meet in order to be ISO 17025: 2017 compliant.

2. As a part of ISO 17025: 2017 standards, laboratories are required to manage and maintain Standard Operating Protocol (SOPs), test methods, test requests and testing instructions, staff training, and instrument maintenance and calibration. Managing all these requirements is important to maintain operational quality and efficiency in operations. Therefore, the presentation will highlight where a LIMS can assist in creating a quality management system to follow ISO 17025 regulatory guidelines.

The vast majority of US states and other countries require quality control testing of cannabis and cannabis processed products prior to release for distribution. The purpose of product testing is to provide patients with the assurance that the medicine is potent and pure and safe for use. Analytical testing also assures that the contents match the label claim, that there is batch to batch consistency, and the product is potent and pure throughout shelf life. Each state and country has its own set of testing requirements and regulations for the analytical laboratories. With these requirements come challenges for both the regulators and the regulated industry.

Learning Objectives:

1. Participants will learn how medical cannabis products are tested and the quality standards
2. Participants will learn about the regulatory testing requirements in the US and other countries
3. Participants will appreciate the various testing challenges as state programs evolve

What makes cannabis potency analysis different from other testing done on cannabis? It is the only test for which there is no “pass” or “fail” outcome but rather the result determines the monetary value and optimal use of cannabis.

As the legal cannabis industry gains legitimacy on an international level, new regulations are changing the marketplace. While the regulated sale of cannabis creates myriad business opportunities, those same regulations lay the groundwork for new and increased regulatory scrutiny. Many of the testing requirements of cannabis are fulfilled by laboratories (e.g., residual solvents, heavy metals, pesticides) but in-house testing is becoming more popular with cannabis companies. Forward-thinking businesses are increasing in-house testing to refine their products, increase quality control, and create an extra line of defence to comply with ever-increasing regulatory requirements.

Today, the HPLC is considered the “gold standard” for testing cannabis potency. Yet, THC and CBD measurements vary widely across testing laboratories using HPLCs. Moreover, there is no universal cannabis potency testing protocol to enable standardization. There have also been reports, particularly in the United States, that licensed laboratories bump up potency results to satisfy customers.

The HPLC does not offer a practical and efficient solution to meet the growing demand for in-house testing solutions along the cannabis supply chain. The capex and opex costs linked to the HPLC pose a challenge to most industry players. Beyond the high cost of an HPLC device, testing requires a skilled lab technician to operate, complex sample preparation, use and disposal of hazardous materials, interpretation of results, all while the sample itself is destroyed.

In the best-case scenario, the HPLC is effective for single flower accuracy but it is not viable for reaching analytical conclusions related to batch consistency challenged by the flower’s heterogenous nature; no two flowers are the same. HPLC testing is not efficient for high frequency on-line testing and for providing results in real time for decision making on the spot, whether it be for R&D, QA or transactional support.

NIR spectroscopy (NIRS), however, offers a viable alternative. It is non-destructive since it tests samples in the solid phase leaving flowers intact, it is easy to use, quick, affordable, accurate when combined with the right data science, no special skillset is required to operate, there are is not residual hazardous waste and its small footprint enables portability.

GemmaCert sees a rising demand for new spectroscopy-based solutions, understands that in-house testing will become increasingly popular with cannabis companies and the sooner rather than later point-of-sale testing will prove standard for business-to-business cannabis transactions. GemmaCert’s technology is best positioned for transactional and comparative purposes, offering in-the-moment information that a third-party laboratory cannot. As a result, GemmaCert is on track to become the field leader for in-house testing in the cannabis industry.

Supercritical fluid extraction (SFE) has been studied and optimized for a variety of purposes in the food and nutraceutical industries. However, optimization data related to the use of SFE for extracting cannabinoids from Cannabis sativa is limited. This talk will focus on how cannabinoid extraction can be optimized by altering the static soak and dynamic flow durations of CO2 while maintaining a consistent solvent-mass to feed-mass ratio. Mass balance and extraction efficiency data will be presented and discussed.

The endocannabinoid system (ECS) is a physiological system that occurs within all mammals and is responsible for maintaining homeostasis and keeping the body in a state of wellbeing, helping us to “eat, sleep, relax and forget” (Americans for Safe Access, 2017; Pettinato, 2017). Initially, most research into the endocannabinoid system was focused on the mechanisms that affect physical health (Martin, 1991). However, there is a growing body of research demonstrating the role that the endocannabinoid system plays in mental health and mood regulation (Walsh et al. 2017). As a result, mental health clinicians often do not have a clear understanding of what the endocannabinoid system is, how it can affect moods, and how exogenous cannabinoids such as cannabis can affect moods, emotions, and related conditions (Feingold, Weiser, Rehm & Lev-Ran, 2015). The purpose of this presentation is to provide a brief overview of the endocannabinoid system, current research on exogenous cannabinoids’ impact on mood regulation, and the potential positive therapeutic impacts of cannabis on mental health and implications for clinical practice.

Learning Objectives:

1. Participants will understand the role that the endocannabinoid system can have impacting mood.
2. Participants will how mental health conditions may be positively impacted by cannabis.

Quantitative methods for residual pesticides and mycotoxins analysis in cannabis should provide reliable coverage and robust methodology for the entire list of analytes to fulfill the state mandated safety tests.

The detection sensitivity and specificity offered by LC/MS/MS is advantageous for determining trace levels of most pesticides and mycotoxins in complex matrices. However, not all pesticides ionize efficiently by conventional ionization techniques such as electrospray or atmospheric pressure chemical ionization. In such cases, trace level detection of pesticides in the presence of a highly complex matrix can be challenging and variable leading to inconsistencies in the results. The combination of LC-MS/MS and GC-MS/MS utilises the advantages of both techniques and can provide quantitative and confirmatory analysis of challenging compounds that can be analysed by either approach.

In this study, a comprehensive evaluation of pesticide analysis in cannabis flower matrix was performed using both analytical techniques. Sample extraction procedures were optimized and a simple dispersive SPE method was used for clean-up of the initial acetonitrile extract.

Methods met the regulatory requirements for cannabis pesticide residues and mycotoxins testing in the State of California. Overall method performance was evaluated by assessing recovery, matrix suppression, linearity, and sensitivity. The results from accuracy, precision and evaluation of matrix effects will be discussed.

Learning Objectives:

1. Workflow for the analysis of pesticide residues and mycotoxins in cannabis using both LC-MS/MS and GC-MS/MS
2. Sample preparation using dSPE cleanup to reduce matrix effects for trace level detection of pesticides in cannabis.

Several clinical and preclinical studies implicate abnormal endocannabinoid functioning and neuroinflammation as possible mechanisms in the pathophysiology of autism. Correcting these abnormalities may result in reducing or alleviating symptoms such as anxiety, aggression, insomnia, and self-injurious behaviors. We will also discuss the possible benefits and adverse effects that may be attributed to the use of cannabis in this population.

Learning Objectives:

1. To understand how and why cannabis therapy broadly impacts maladaptive behaviors commonly seen in autistic patients.
2. To be able to weigh the possible benefits and risks of cannabis therapy in this population.

In 2018 with more and more consumers having access to legal Cannabis the interest in incorporating cannabis in to their lifestyles is becoming more and more prevalent. Len May, founder of Endocanna Health, a research and development bio-technology company specializing in Direct-to-Consumer genetic testing, will walk session goers through how human DNA and the endocannabinoid system interact with Cannabis. This session will walk through the scientific breakthroughs that have been discovered using human genetics to find compatibility for individuals and the cannabis plant.

Learning Objectives:

1. Developing Cannabis products based on Human genetics
2. The latest breakthroughs in Cannabis and genetics research
3. The science of Genetics and Cannabis
4. How to best educate the Cannabis consumer about Cannabis and the Endocannabinoid system

As the cannabis industry continues to grow, it places a higher demand on producers and processing facilities to meet the increasing mandate for clean, refined cannabis-based products. While there are several commercialized solutions for solvent removal, concentration, and distillation at the lab and proof-of-principle scales, very few strategies exist for handling the amounts of solvent required to process cannabis at the industrial scale. This talk will review the current state of cannabis processing technology and where current processing bottlenecks exist. Strategies for scaling several evaporation technologies including wiped film (falling or rising film), rotary evaporation, and short path distillation will be discussed, as well as where each process fits in the cannabis processing workflow. Finally, recommendations will be given for a complete industrial scale cannabis processing workflow from handling of biomass, ethanol generation and extraction, extract concentration, and isolate purification.

Whole food plant-based diets and medical cannabis have shared and continues to share similar levels of scrutiny, doubt, and stigma by the traditional medical community. One reason for the medical community distrusting the science behind whole food plant-based diets, medical cannabis, and the endocannabinoid system may be because the information is not usually taught in traditional educational platforms such as universities, medical schools or other allied health schools, or specialty sponsored medical continuing education conferences. The information is often rejected as hearsay or anecdotal despite mounting evidence that both whole food plant-based diets and medical cannabis can contribute positively as a sole therapeutic modality or in conjunction with traditional therapeutic treatments. There is a lot of public interest in medical cannabis as a solo treatment or as an adjunct treatment for many medical conditions. The question is if evidence shows that medical cannabis is efficacious? There is also a lot of public interest surrounding how diet and lifestyle may help boost the immune system and transform the body into a healing machine. There is evidence linking the synergistic mechanisms of action between whole food plant-based nutrition with medical cannabis leading to positive health outcomes. I will present my methods for treating patients and patient outcomes using case reports as examples. I will support my therapeutic management of patients, combining a whole food plant-based diet with medical cannabis, with evidence-backed information. I will discuss the rationale for the nutrition and lifestyles changes, the importance of an intact microbiome, and explain the endocannabinoid system and its involvement in biologic systems, and the use of medical cannabis.

This knowledge is imperative for all physicians especially at a time when the world regulatory landscape is changing rapidly. The US DEA removed cannabidiol from the Controlled Substances Act and the World Health Organization is recommending that cannabis and all cannabinoids be removed from DEA schedule I designation.

Learning Objectives:

1. Understand how a whole food all plant diet can transform the body’s internal environment and support the immune system.
2. Understand how medical cannabis can help to as a therapeutic option as well as help to mitigate side effects from traditional therapeutic treatments.

With the legalization process currently taking place in the US, finding new techniques for the fast, cheap, and comprehensive analysis of Cannabis sativa components has become a major point of interest. Different analytical tools have been widely used for the characterization of the main components of the plant, cannabinoids and terpenes. Both these classes of compounds can be analyzed with the use of the gas chromatograph coupled with the mass spectrometer (GC-MS), and with the vacuum ultraviolet detector (GC-VUV).

In this research, we used these two technologies to analyze cannabinoids and terpenes found in C. sativa; the sensitivity of the multiple reaction monitoring (MRM) mode used in the GC-MS allowed for the analysis of impurities, while the GC-VUV was more adapt for a potency testing. Terpenes were analyzed on GC-VUV due to the possibility of the instrument to differentiate between isobaric compounds, and to deconvolve coeluting peaks that otherwise would need a longer chromatographic separation.

Learning Objectives:

1. Why GC is a necessary tool for R&D and QC labs in the Cannabis world.
2. How new technologies are advancing to give a more comprehensive understanding of the plant.

If your lab has decided to apply for ISO/IEC 17025 accreditation as your state requires it or to demonstrate the reliability of your lab results to potential customers, you may think what next? Achieving and maintaining the necessary compliance such as ISO 17025:2017 accreditation is a time-consuming, costly, and complicated process. It includes managing and tracking employee training and competency, Standard Operating Protocol (SOP's) management, risk management, and instrument maintenance and calibration. An informatics solution such as Laboratory Information Management System (LIMS) can make this job much easier.

1. ISO 17025 Certification helps cannabis testing labs to prove their technical capabilities, strong commitment to quality, operational efficiency and management practices. The presentation will highlight both the management and technical requirements that a cannabis testing laboratory should meet in order to be ISO 17025: 2017 compliant.

2. As a part of ISO 17025: 2017 standards, laboratories are required to manage and maintain Standard Operating Protocol (SOPs), test methods, test requests and testing instructions, staff training, and instrument maintenance and calibration. Managing all these requirements is important to maintain operational quality and efficiency in operations. Therefore, the presentation will highlight where a LIMS can assist in creating a quality management system to follow ISO 17025 regulatory guidelines.

What makes cannabis potency analysis different from other testing done on cannabis? It is the only test for which there is no “pass” or “fail” outcome but rather the result determines the monetary value and optimal use of cannabis.

As the legal cannabis industry gains legitimacy on an international level, new regulations are changing the marketplace. While the regulated sale of cannabis creates myriad business opportunities, those same regulations lay the groundwork for new and increased regulatory scrutiny. Many of the testing requirements of cannabis are fulfilled by laboratories (e.g., residual solvents, heavy metals, pesticides) but in-house testing is becoming more popular with cannabis companies. Forward-thinking businesses are increasing in-house testing to refine their products, increase quality control, and create an extra line of defence to comply with ever-increasing regulatory requirements.

Today, the HPLC is considered the “gold standard” for testing cannabis potency. Yet, THC and CBD measurements vary widely across testing laboratories using HPLCs. Moreover, there is no universal cannabis potency testing protocol to enable standardization. There have also been reports, particularly in the United States, that licensed laboratories bump up potency results to satisfy customers.

The HPLC does not offer a practical and efficient solution to meet the growing demand for in-house testing solutions along the cannabis supply chain. The capex and opex costs linked to the HPLC pose a challenge to most industry players. Beyond the high cost of an HPLC device, testing requires a skilled lab technician to operate, complex sample preparation, use and disposal of hazardous materials, interpretation of results, all while the sample itself is destroyed.

In the best-case scenario, the HPLC is effective for single flower accuracy but it is not viable for reaching analytical conclusions related to batch consistency challenged by the flower’s heterogenous nature; no two flowers are the same. HPLC testing is not efficient for high frequency on-line testing and for providing results in real time for decision making on the spot, whether it be for R&D, QA or transactional support.

NIR spectroscopy (NIRS), however, offers a viable alternative. It is non-destructive since it tests samples in the solid phase leaving flowers intact, it is easy to use, quick, affordable, accurate when combined with the right data science, no special skillset is required to operate, there are is not residual hazardous waste and its small footprint enables portability.

GemmaCert sees a rising demand for new spectroscopy-based solutions, understands that in-house testing will become increasingly popular with cannabis companies and the sooner rather than later point-of-sale testing will prove standard for business-to-business cannabis transactions. GemmaCert’s technology is best positioned for transactional and comparative purposes, offering in-the-moment information that a third-party laboratory cannot. As a result, GemmaCert is on track to become the field leader for in-house testing in the cannabis industry.

Quantitative methods for residual pesticides and mycotoxins analysis in cannabis should provide reliable coverage and robust methodology for the entire list of analytes to fulfill the state mandated safety tests.

The detection sensitivity and specificity offered by LC/MS/MS is advantageous for determining trace levels of most pesticides and mycotoxins in complex matrices. However, not all pesticides ionize efficiently by conventional ionization techniques such as electrospray or atmospheric pressure chemical ionization. In such cases, trace level detection of pesticides in the presence of a highly complex matrix can be challenging and variable leading to inconsistencies in the results. The combination of LC-MS/MS and GC-MS/MS utilises the advantages of both techniques and can provide quantitative and confirmatory analysis of challenging compounds that can be analysed by either approach.

In this study, a comprehensive evaluation of pesticide analysis in cannabis flower matrix was performed using both analytical techniques. Sample extraction procedures were optimized and a simple dispersive SPE method was used for clean-up of the initial acetonitrile extract.

Methods met the regulatory requirements for cannabis pesticide residues and mycotoxins testing in the State of California. Overall method performance was evaluated by assessing recovery, matrix suppression, linearity, and sensitivity. The results from accuracy, precision and evaluation of matrix effects will be discussed.

Learning Objectives:

1. Workflow for the analysis of pesticide residues and mycotoxins in cannabis using both LC-MS/MS and GC-MS/MS
2. Sample preparation using dSPE cleanup to reduce matrix effects for trace level detection of pesticides in cannabis.

As the cannabis industry continues to grow, it places a higher demand on producers and processing facilities to meet the increasing mandate for clean, refined cannabis-based products. While there are several commercialized solutions for solvent removal, concentration, and distillation at the lab and proof-of-principle scales, very few strategies exist for handling the amounts of solvent required to process cannabis at the industrial scale. This talk will review the current state of cannabis processing technology and where current processing bottlenecks exist. Strategies for scaling several evaporation technologies including wiped film (falling or rising film), rotary evaporation, and short path distillation will be discussed, as well as where each process fits in the cannabis processing workflow. Finally, recommendations will be given for a complete industrial scale cannabis processing workflow from handling of biomass, ethanol generation and extraction, extract concentration, and isolate purification.

The use of cannabis to treat the symptoms of cancer and associated treatments is well known, but a growing body of evidence shows how cannabis can also be used as a direct anticancer agent. In this presentation, preclinical studies showing the anticancer effects of specific cannabinoids will be discussed, along with human reports of remissions from aggressive cancers after using high doses of cannabinoids.

Learning Objectives:

1. Describe the basic biological mechanisms by which cannabinoids have been shown to inhibit cancers
2. Understand the human and clinical evidence demonstrating how preclinical effects are translating to humans

Dr. Sulak will review the evidence supporting the use of cannabis to not only treat serious disease, but to prevent them and maintain health, with practical and easy to implement dosing strategies. This lecture will also cover non-cannabis influences on our endocannabinoid physiology and focus on chronic conditions including sleep disorders, cardiovascular disease, neurologic injury, obesity and diabetes, and more.

The endocannabinoid system (ECS) is a physiological system that occurs within all mammals and is responsible for maintaining homeostasis and keeping the body in a state of wellbeing, helping us to “eat, sleep, relax and forget” (Americans for Safe Access, 2017; Pettinato, 2017). Initially, most research into the endocannabinoid system was focused on the mechanisms that affect physical health (Martin, 1991). However, there is a growing body of research demonstrating the role that the endocannabinoid system plays in mental health and mood regulation (Walsh et al. 2017). As a result, mental health clinicians often do not have a clear understanding of what the endocannabinoid system is, how it can affect moods, and how exogenous cannabinoids such as cannabis can affect moods, emotions, and related conditions (Feingold, Weiser, Rehm & Lev-Ran, 2015). The purpose of this presentation is to provide a brief overview of the endocannabinoid system, current research on exogenous cannabinoids’ impact on mood regulation, and the potential positive therapeutic impacts of cannabis on mental health and implications for clinical practice.

Learning Objectives:

1. Participants will understand the role that the endocannabinoid system can have impacting mood.
2. Participants will how mental health conditions may be positively impacted by cannabis.

Several clinical and preclinical studies implicate abnormal endocannabinoid functioning and neuroinflammation as possible mechanisms in the pathophysiology of autism. Correcting these abnormalities may result in reducing or alleviating symptoms such as anxiety, aggression, insomnia, and self-injurious behaviors. We will also discuss the possible benefits and adverse effects that may be attributed to the use of cannabis in this population.

Learning Objectives:

1. To understand how and why cannabis therapy broadly impacts maladaptive behaviors commonly seen in autistic patients.
2. To be able to weigh the possible benefits and risks of cannabis therapy in this population.

Whole food plant-based diets and medical cannabis have shared and continues to share similar levels of scrutiny, doubt, and stigma by the traditional medical community. One reason for the medical community distrusting the science behind whole food plant-based diets, medical cannabis, and the endocannabinoid system may be because the information is not usually taught in traditional educational platforms such as universities, medical schools or other allied health schools, or specialty sponsored medical continuing education conferences. The information is often rejected as hearsay or anecdotal despite mounting evidence that both whole food plant-based diets and medical cannabis can contribute positively as a sole therapeutic modality or in conjunction with traditional therapeutic treatments. There is a lot of public interest in medical cannabis as a solo treatment or as an adjunct treatment for many medical conditions. The question is if evidence shows that medical cannabis is efficacious? There is also a lot of public interest surrounding how diet and lifestyle may help boost the immune system and transform the body into a healing machine. There is evidence linking the synergistic mechanisms of action between whole food plant-based nutrition with medical cannabis leading to positive health outcomes. I will present my methods for treating patients and patient outcomes using case reports as examples. I will support my therapeutic management of patients, combining a whole food plant-based diet with medical cannabis, with evidence-backed information. I will discuss the rationale for the nutrition and lifestyles changes, the importance of an intact microbiome, and explain the endocannabinoid system and its involvement in biologic systems, and the use of medical cannabis.

This knowledge is imperative for all physicians especially at a time when the world regulatory landscape is changing rapidly. The US DEA removed cannabidiol from the Controlled Substances Act and the World Health Organization is recommending that cannabis and all cannabinoids be removed from DEA schedule I designation.

Learning Objectives:

1. Understand how a whole food all plant diet can transform the body’s internal environment and support the immune system.
2. Understand how medical cannabis can help to as a therapeutic option as well as help to mitigate side effects from traditional therapeutic treatments.

Imagine the need for agriculture being removed completely from the cannabis supply chain.

Cellibre’s vision is to leverage biology to make products more sustainable, efficiently and reliably across industries by employing the multidisciplinary science known as cellular agriculture. We leverage our expertise in cellular agriculture to turn cells into specialized, sustainable factories for the manufacture of globally significant products at scale.

Cells are inherently superior producers of products for a variety of reasons. First, nature’s machinery can conduct complex reactions at nanoscale precision that are difficult and, in some cases, impossible to achieve by any other means. This ability leads to improved quality and consistency over many legacy manufacturing processes and enable the potential to develop completely novel products. Next, cells copy themselves through cellular division which serves to multiple their natural brick and mortar infrastructure, often with minimal nutrients. This means that production scales itself. In addition, cells repair themselves. Cells have natural machinery that reacts when cell production is impaired to repair the damaged parts and return to regular course. This translates into lower maintenance costs and less downtime. Lastly, cell-based production is uniquely sustainable. Cells very efficiently convert inputs, typically low cost media, into high-value products. In addition, byproducts created as a resulted of bioproduction are generally non-toxic because harmful substances would terminate the cells and stop production of all materials, including the toxins themselves.

Cellibre's strategic focus is deploying its expertise in cellular agriculture to revolutionize the way cannabis extracts and cannabinoid-based medicines are sourced, produced and consumed. The resultant outputs from the bio-based manufacture of any cannabinoid (including minor cannabinoids) will be high-quality, sustainable and specific cannabinoids for use across applications. The significant deficiencies throughout the current cannabinoid supply chain, the resource requirements in the agricultural process and the evolving regulatory environment globally provide Cellibre an immense opportunity to disrupt a $50+ billion market via the production of high-quality, sustainable, specific and pure, medical-grade natural products.

Learning Objectives:

1. What is cellular agriculture and the science of synthetic biology
2. Why is fermentation an advantaged method for the production of cannabis extracts on virtually all metrics

In 2018 with more and more consumers having access to legal Cannabis the interest in incorporating cannabis in to their lifestyles is becoming more and more prevalent. Len May, founder of Endocanna Health, a research and development bio-technology company specializing in Direct-to-Consumer genetic testing, will walk session goers through how human DNA and the endocannabinoid system interact with Cannabis. This session will walk through the scientific breakthroughs that have been discovered using human genetics to find compatibility for individuals and the cannabis plant.

Learning Objectives:

1. Developing Cannabis products based on Human genetics
2. The latest breakthroughs in Cannabis and genetics research
3. The science of Genetics and Cannabis
4. How to best educate the Cannabis consumer about Cannabis and the Endocannabinoid system

The cannabis industry has realized that not just one or two compounds of the plant are important for a variety of medical indications. A plethora of metabolites, e.g. terpenes, flavonoids and cannabinoids, give rise to the desired effects. Such chemical makeups are not only dictated by the strain/cultivar, but also influenced by grow methods, drying and curing, and also the extraction method. Unfortunately, it is mostly overlooked how these processes lead to high quality, reliable products. This talk will discuss our latest findings on how to control the molecular makeup throughout the production pipeline.

Learning Objectives:

1. The audience will learn about the changes that happen to cannabis and its bioactive molecules during different production stages.
2. The audience will learn about ways of how to control such changes and even consciously manipulate molecular profiles.

Supercritical fluid extraction (SFE) has been studied and optimized for a variety of purposes in the food and nutraceutical industries. However, optimization data related to the use of SFE for extracting cannabinoids from Cannabis sativa is limited. This talk will focus on how cannabinoid extraction can be optimized by altering the static soak and dynamic flow durations of CO2 while maintaining a consistent solvent-mass to feed-mass ratio. Mass balance and extraction efficiency data will be presented and discussed.

It can often be a very challenging task to understand what rules and regulations you are responsible for in a cannabis business. Being out of compliance can be a costly mistake with huge fines or even a loss of licensure at stake. Learn about what resources are available for people just like yourself that can help you save time, money, and sleep better at night.

The vast majority of US states and other countries require quality control testing of cannabis and cannabis processed products prior to release for distribution. The purpose of product testing is to provide patients with the assurance that the medicine is potent and pure and safe for use. Analytical testing also assures that the contents match the label claim, that there is batch to batch consistency, and the product is potent and pure throughout shelf life. Each state and country has its own set of testing requirements and regulations for the analytical laboratories. With these requirements come challenges for both the regulators and the regulated industry.

Learning Objectives:

1. Participants will learn how medical cannabis products are tested and the quality standards
2. Participants will learn about the regulatory testing requirements in the US and other countries
3. Participants will appreciate the various testing challenges as state programs evolve

Todays drug programs in schools use abstinence based approaches that are centered around the idea that avoiding marijuana is the only acceptable option and often rely on the stigmatization of drug use and users. Although there are many reasons why youth may use cannabis, cannabis education has framed use in very narrow ways and ignored the diverse spectrum of use patterns. Youth often get much of their information online, and many older programs have ignored the digital context of how our generation obtains, explores, and generates information about marijuana use. Education must provide honest, age-appropriate information, which will ultimately arm young people with the skills necessary to take personal responsibility for their health and decision making. Youth will encounter cannabis, so honest information and ongoing discussions about cannabis will help them navigate the changing legal landscape and experiences with friends, family and acquaintances.

Learning Objectives:

1. Heavy handed and fear based approaches to drug education can alienate young people and undermine the credibility of the education efforts.
2. Emerging research suggests the importance of including harm reduction strategies in drug education to address the needs of young people, including those who may be using cannabis.

Cannabis Sciences 2019

For the second year in a row, LabRoots is pleased to announce the 2019 Cannabis Sciences Virtual Event. LabRoots will host the 2nd Annual event March 27-28, 2019. The Cannabis Sciences planning committee has carefully planned and selected speakers that best embody the overall challenges, opportunities, and issues in the current landscape around cannabis sciences.

The theme for this year's event is State of Cannabis: latest update on research, science, and legislation with the following tracks:

Cannabis Advances & Technology Updates

Machine Learning in Cannabis

Plant Genetics

Personalized Medicine

Making Cannabis Mainstream

Cannabis and Your Health

Regulatory Landscape

Extraction, Purification and Cultivation

Analytical Testing

Methods and Technologies for Cannabis Labs

Data Management

Don't miss the opportunity to participate in this groundbreaking conference, which is absolutely free to all participants. Enjoy our Leaderboard, where you can move around the entire event, earning points for a chance to win one of LabRoots most popular t-shirts.

Call for Posters — Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Plan now to have your poster included in the 2019 Cannabis Sciences Virtual Event. Submission is free. Submit your abstract here.

Continuing Education
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this event, you can earn 1 Continuing Education credit per presentation for a maximum of 32 credits.

Dr. Dustin Sulak is an integrative osteopathic physician and medical cannabis expert. His clinical practice focuses on treating refractory conditions in adults and children. Dr. Sulak is the founder of Integr8 Health, a medical practice in Maine that follows over 8,000 patients using medical cannabis, Healer.com, a medical cannabis patient education resource. He sits on the board of directors of the Society of Cannabis Clinicians, has published in the peer-reviewed literature, and lectures to healthcare providers internationally on the clinical applications of cannabis.

Gia is currently working as an independent consultant supporting the agricultural biotechnology industry, after leaving in 2017 as the Director of Project Planning with Arcadia Biosciences managing the program portfolio of the company. Prior to that she managed the Analytical Science and Regulatory Support group for nearly 5 years, performing crop analysis and generating data for regulatory approvals through the FDA, USDA and multiple international agencies. Before that she worked as a principal scientist also at Arcadia in the Nitrogen Use Efficiency Program generating metabolic and protein fingerprints for engineered plant lines. She has also worked as a Research Technician at Rice University between undergrad and graduate school. Gia has a PhD in Biochemistry from Rice University (2007) and graduated from Indiana University (2001) with a BS in Biology, where she studied plant natural products and protein chemistry, respectively.

Jan Roberts, LCSW

CEO, Director of Translational Research, International Research Center on Cannabis and Mental Health

Jan Roberts is a recognized leader in the field of cannabis and mental health. Ms. Roberts is
a licensed clinical social worker and the Chief Executive Officer and Director of Translational Research at the International Research Center on Cannabis and Mental Health, a collaborative research institute located in New York that bridges university and community-based projects. In addition, Ms. Roberts is the founder and CEO of Partners in Health and Wellbeing, one of the largest multi-site mental health and wellness practices in the mid-Atlantic region in the United States. Ms. Roberts teaches at the NYU Silver School of Social Work, where she will be awarded her doctorate in May 2019, and at CUNY Hunter College's Silberman School of Social Work. In addition, Ms. Roberts is a governor-appointed member on the Delaware Medical Marijuana Act Advisory Committee and is the current Guest Editor for the Clinical Social Work Journal's upcoming special issue on cannabis and mental health. Ms. Roberts lives in New York and sees patients at her practice in Manhattan.

Arun Apte is a serial entrepreneur with over two decades of bioinformatics and hands on laboratory experience. He is currently responsible for galvanizing corporate financial performance, market reputation and core team performance, with a particular interest in developing new markets and forging strategic alliances with key partners.
Prior to founding CloudLIMS, he found PREMIER Biosoft forging strategic partnerships with Thermo, Agilent, SCIEX and other mass spectrometry instrument companies. Arun Apte holds a B.A. in molecular and cell biology and biophysics from the University of California at Berkeley. He has been published extensively on bioinformatics.

A skilled R&D chemist with a Ph.D. in Biotechnology from Tel Aviv University with experience from both academia and business, including as Synthetic Chemistry Team Leader at StoreDot and Head of Chemistry at Panaxia, a pioneering company in the medical cannabis industry. Today serves as the VP of Research and Compliance at GemmaCert.

Marcel Bonn-Miller, PhD

Research Director, The Lambert Center for the Study of Medicinal Cannabis & Hemp, Adjunct Assistant Professor of Psychology, Department of Psychiatry, University of Pennsylvania School of Med

Dr. Marcel O. Bonn-Miller earned a BA in psychology and PhD in clinical psychology from the University of Vermont. He completed a pre-doctoral clinical psychology internship at the Veterans Affairs Palo Alto Health Care System and a joint postdoctoral fellowship at the Veterans Affairs Palo Alto Health Care System & Stanford University School of Medicine.
Widely considered one of the early and leading research pioneers in the field of cannabis and mental health, Dr. Bonn-Miller has conducted seminal work on the interrelations between cannabis and a range of health conditions, including pain, anxiety, HIV, PTSD, and sleep disorders. Dr. Bonn-Miller brings a unique and diverse perspective to cannabinoid therapeutics, having worked within medical center and academic settings for over a decade and with industry for the past 5 years. He serves on the editorial boards of several scientific journals, has published well over 125 peer-reviewed empirical publications on cannabis, and has received dozens of Federal and State grants to support his research.

Ben is the founder and CEO of Cellibre, a next-generation biotechnology company that is ushering in the next great industrial revolution by treating biology as a manufacturing technology, turning cells into specialized, sustainable factories for the manufacture of globally significant products at scale. Ben formally worked with Dr. J Craig Venter and Nobel Laureate Dr. Ham Smith as the Vice President of Corporate Development and Strategy at Synthetic Genomics (SGI) where he was responsible for defining, evolving and implementing SGI's strategy across all of its franchises. Ben joined SGI from Millennium Health, a leading medication solutions company focused on solving the opioid epidemic, where he led the strategy and corporate development efforts. Prior to joining industry, Ben had a nine-year tenure on Wall Street, where he executed over $20 billion in transactions. Ben earned his MBA from Carnegie Mellon University's Tepper School of Business and his B.S. in Mechanical Engineering from Case Western Reserve University. He is also the co-founder of Divitempus Ventures, ConvenCare and the 32/21 Foundation.

Dr. Kent Crowley has over 30 years experience in the pharmaceutical industry and clinical medicine. He obtained his Doctor of Pharmacy from the University of California, San Francisco; completed an ASHP Accredited Residency with Kaiser Permanente. He is an Advanced Fellow and Diplomat of the American Academy of Anti-Aging Medicine.
At Silver State Trading, a 40,000 sq.ft. Clean Green cultivation and production facility in Sparks, NV, Dr. Crowley serves as the Director of Research and Development, overseeing the production of Trokie® products and future patents. Dr. Crowley is the founder and creator of Trokie®, a patented buccal delivery system for cannabis (U.S. Patent No.: 9,675,656 B2) and runs the California operations for Trokie California Inc.
Dr. Crowley serves as the Chief Medical Officer of the Palliative Care Corp, a clinic in Huntington Beach, CA that has treated over 3000 patients incorporating cannabis in disease state treatment and symptoms management, whether as a primary treatment or complementary to traditional and/or other modalities. He has recently published on this effort in Frontiers in Neuroscience, Aug 2018.
Dr. Crowley is a member of the Society of Cannabis Clinicians and on the Research Subcommittee, a member of the International Cannabinoid Research Society and a member of the Integrative Think Tank for University of California Irvine, Center for the Study of Cannabis.

James Eaves received his Ph.D. in Agricultural Economics from the University of California, Davis. Today, he is a management professor at Université Laval, where he is part of a research group that aims to find ways to increase the profitability of growing cannabis indoors and in greenhouses. He is a regular invited speaker at cannabis conferences across North America, writes for Canada's leading cannabis trade journal, and his award winning research has been discussed in numerous media outlets, including The Washington Post, Newsweek, and the CBC.

Dr. Patricia Frye is a medical cannabis specialist and consultant who evaluates adult and pediatric patients for the use of cannabis medicine in the treatment of chronic pain and other serious, debilitating conditions, like neurodegenerative diseases, autism, seizures, autoimmune, and psychiatric illnesses.
A graduate of the University of Maryland School of Medicine, where she also completed her pediatric residency, Dr. Frye continued her post-graduate training in anesthesiology at Baylor College of Medicine in Houston, TX. She then moved to Southern California where she practiced pediatrics for Southern California Permanente Group until she retired.
In 2015, Dr. Frye was asked to consider a California cannabis telemedicine position, and it was then that she first learned of the healing benefits of the cannabis plant. Since that time, Dr. Frye has managed over 5,000 patients and provides educational consultations to patients worldwide.
Dr. Frye is certified by the American Board of Pediatrics, and professionally certified in Cannabis Science and Medicine by the University of Vermont Larner College of Medicine. She is a diplomat of the Society of Cannabis Clinicians, a member of the Association of Cannabis Specialists and a fellow of the Academy of Integrative Pain Management.
In addition to direct patient care, Dr. Frye lectures extensively on cannabis medicine for healthcare provider groups, patient groups, and cannabis education organizations.
She is the author of "The Medical Marijuana Guide: Cannabis and Your Health", a book that covers the history, politics, and use of cannabis as medicine.

Joe Grumbine has been cultivating cannabis as well as extracting and compounding therapeutic topicals and elixirs for 30+ years. In 2007 he founded Unit d patients collective in Garden Grove and consulted and provided cannabis and cannabis infused products to more than 4000 clients. In addition he managed and consulted numerous outdoor, greenhouse and indoor cultivation projects
In 1999 Joe opened Willow Creek Springs botanical garden and nursery where he ran a permaculture farm that produces a variety of healing herbs Willow Creek Springs has been a venue for many workshops, classes and horticultural therapy projects. Joe and his wife Liz have been creating therapeutic lotions, creams, and other topicals and have created a line of Cbd and The infused products that have been distributed nationwide and are currently in the beginning stages of two IRB studies.
In 2009 Joe founded The Human Solution International 501c3 to educate and support victims of the drug war. Joe used the support during a six year battle with the State of California and ultimately prevailed. The Human Solution has organized grass roots support for cannabis defendants worldwide and have been instrumental in several high profile cases ending in acquittal or dismissal. The Human Solution also has a prison outreach program where they support cannabis prisoners especially those serving life and "De facto" life sentences. The Human Solution International is an all volunteer organization that advocates decriminalization of cannabis rather than restrictive "legalization." They are committed to working to ending cannabis prohibition entirely.
As CEO of Willow Creek Springs and The Human Solution International, Joe Grumbine has been working with physicians and advocates to further the understanding of cannabis therapy and to support victims of the drug war.

Matt Haskin was the founder and previous CEO of CannaSafe Analytics, which, under his vision and leadership, became the first cannabis laboratory in the United States to be awarded an ISO 17025:2005 accreditation in 2012. He holds a Bachelor of Science degree from Columbia State University and has extensive experience in both domestic and international business. A chronic entrepreneur, Matt struck upon the concept of a medical cannabis laboratory in late 2009 after observing close family and friends struggle with concerns over the safety of the cannabis they used as medicine. With no industry established protocols or methods for testing cannabis, Matt set out to develop a lab that would set the standard and earn the trust of its clients. In February 2015 Matt was appointed Vice Chair of the Independent Laboratory Advisory Committee to the state of Nevada. The Committee makes policy recommendations on the state's cannabis program. Matt is also a member of the AOCS Cannabis Expert Panel, sits on the board of directors of the California Minority Alliance and is a member of the Green Standard Working Group. He was honored to be nominated and evaluated for the position of Bureau Chief of the California Bureau of Cannabis Control. Matt sold CannaSafe in October 2016 and now heads up Certus Analytics, a BCC licensed California cannabis compliance laboratory.

Justin Kander is the Patient Coordinator for The Oil Plant, a licensed manufacturer of whole-plant cannabis medicines in California. He has been with the company and its associated brand Aunt Zelda's since July 2015. In 2008, he began collecting research and experiences surrounding the use of cannabis to treat cancer, and eventually published several books on the subject. Justin has presented at medical cannabis conferences to further share information as widely as possible.

Eric Kawka is the founder of Cattis Scientific, a Cannabis startup in Vermont. He focuses his work on developing and implementing Cannabis extraction standards and processes for the quickly growing bio-botanical space. He's particularly interested in establishing scalable extraction methods for a new class of medical cannabis derived products that meet pharmaceutical standards. Eric holds a M.A. in organic chemistry and has significant experience in extraction systems development, start-up ventures, and business development. Eric is an advisor for Cannabis start-ups in Massachusetts, Vermont, Ohio and Florida.

Debra Kimless, M.D. graduated magna cum laude, Phi Beta Kappa from Muhlenberg College with a double major in Natural Sciences and Biology. She attended medical school at Rutgers, and residency at Temple University Hospital and is a board-certified Anesthesiologist with a subspecialty certification in Pain Medicine and is recently board certified by the American/International Lifestyle Medicine Board.
Motivated by her mother who, at the end of her life suffered with intractable pain and who responded paradoxically to opiates, Dr. Kimless traveled the world to learn if medical cannabis could have been a treatment option. She studied under the most respected experts in cannabis medicine and research and has become a passionate champion for medical cannabis.
In addition to being the Medical Director of ForwardGro, a medical cannabis cultivation and processing company in Maryland, Dr. Kimless shares her knowledge by speaking with physicians and other health care providers, patients and legislators about using medical cannabis as a therapeutic option. She consults with patients, pro bono, treating them with whole food all plant diets and medical cannabis, and collects patient data and presents the cases at national and international conferences and seminars.
Her passion is to use education to de-stigmatize cannabis and explain how it may be used as an effective medical choice.
In her spare time, Dr. Kimless enjoys sharing her home cooked whole food all plant meals with family and friends. She will never turn down a cup of coffee.

Allegra Leghissa graduated with her PhD in analytical chemistry from the University of Texas at Arlington in July 2018, working under the direction of Prof. Kevin A. Schug. She was born and raised in Bologna, Italy. She left Italy in August 2014 after completing an undergraduate Chemistry degree at the University of Bologna.

At 13, Rylie Maedler has accomplished more than most of us midway into adulthood. Not only is this teenage powerhouse the CEO of her own cannabis company and the founder of a non profit foundation, but she is the driving force behind three laws granting children in her home state of Delaware access to medical cannabis. She travels the world speaking at medical cannabis conferences, advocates for pediatrics to have better access to safe medical cannabis and for advancements in the research of rare diseases using cannabis preparations.

Jahan Marcu, Ph.D., is currently the Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and Director of the Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at cannabis operations. He is co-founder and past-chairman of the CANN subdivision of the Chemical Health and Safety Division (DCHAS) of the American Chemical Society. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine. He has a background in analytical chemistry and molecular pharmacology, he received his Ph.D. for contributions in characterizing the structure and function of the cannabinoid receptors.
He is an author of the American Herbal Pharmacopeia's Cannabis Monograph and serves on multiple expert government, trade association committees, scientific organizations including AHPA, ACS, AOCS, AOAC, ASA, IACM, and IMCPC. And is a court-qualified synthetic cannabinoid and cannabis expert. He has helped create medical cannabis educational training for clinicians and for workers in the medical cannabis industry, and has been invited to speak at many international conferences and universities, including the University of Leiden, Temple University School of Medicine, Princeton Hospital, and Yale University. Dr. Marcu is also a court qualified expert witness on cannabis and synthetic cannabinoids.

Jason Matlock is a doctoral candidate at Michigan State University, working in the Organic Pest Management Laboratory under the Department of Entomology. He holds a Master's Degree in Horticulture from Michigan State University, and a B.S. in Chemistry from Alma College. Mr. Matlock has expert-level knowledge of agricultural management practices, agroecology, pesticide toxicology, and statistical analysis. Prior to graduate studies, he worked in the craft beer and wine industry as a brewer and cellar man. His experience in craft-brewing is directly transferable to commercial cannabis production given it is a stringently regulated, licensed, and process-oriented industry. Furthermore, Mr. Matlock has participated in Michigan's Medical Marijuana Program as a caregiver since 2010.

Len May is CEO and Co-Founder of EndoCanna Health, a bioscience research company specializing in Personalized Medicinal Cannabis using DNA sequencing, and parent company of the EndoCanna Health DNA Test Kit , the most comprehensive personalized Cannabis DNA test and available on the market today.
With over 25 years of experience, Len May, MCS is a pioneer in the medical cannabis industry having held positions such as the President of the Cannabis Action Network, Board Member and Lifetime Member of California Cannabis Association , as well as a stakeholder in some of the industry's most iconic brands. His experience also encompasses a strong understanding of branding and compliance, fundraising, and operations.
As a Certified Medical Cannabis Specialist in Medicinal Genomics, May has an in-depth knowledge of genomics, cannabinoids and terpenes and their interaction with the endocannabinoid system, allowing him to consult on formulations targeted to treat specific conditions. May has a Masters of Medical Cannabis and Endocannabinoid Formulation Specialist Certification from the Institute for the Advancement of Integrative Medicine. His areas of expertise include the workings of the Endocannabinoid system and how genetic expression plays a role in human experiences. In his role as CEO of Endocanna Health, he uses his knowledge of the plant to help modulate those experiences for those looking to incorporate Cannabis into their lives.
Mr. May is an accomplished public speaker having presented on these topics on some of the world's most prestigious stages in his mission to help educate the population about the healing powers of cannabis.

Former commissioner, Deborah Miran, was a member of the Natalie M. LaPrade Maryland Medical Cannabis Commission from 2013- 2016. While serving on the commission, she was also a member of the executive committee, policy, and research subcommittees, and was chair of the education subcommittee. She was responsible for developing education programs for doctors and patients, and was also an integral part of crafting the current regulations. Prior to the commission she was president and founder of Miran Consulting, Inc. There she advised both brand and generic drug makers on the FDA approval process. Ms. Miran was senior director of regulatory affairs for Alpharma, a generic drug manufacturer, where she directed the submission activities for new and abbreviated new drug applications to the FDA. She has spent over 30 years in the US pharmaceutical industry. Ms. Miran received her bachelor of science in chemistry from Iowa State University.

Dr. Moreno-Sanz has authored more than 25 scientific articles and 3 patents describing the role of the endocannabinoid system on pain perception. He holds degrees in Biochemistry and Organic chemistry from the University of Zaragoza, and obtained his PhD in Neurosciences from the Complutense University of Madrid in Spain. He gained broad international experience with long-term fellowships in the Netherlands, Italy and the US, where he has developed most of his career at the University of California, Irvine, working with Prof. Daniele Piomelli, a pioneer of cannabinoid pharmacology. At UCI, he discovered a new class of cannabinoid analgesics devoid of unwanted psychoactivity. In 2017, he participated in the elaboration of the report "The Health Effects of Cannabis and Cannabinoids" by the National Academies of Sciences. In 2018, he founded Abagune Research, a privately-owned company that provides R&D solutions to the cannabis industry.

Evan Moser is the Chief Engineer of Deutsche Companies Located in Charlotte, North Carolina. Evan graduated from Iowa State University in 2010, where he received a B.S. in Chemical Engineering. At Iowa State, Evan worked for Department of Energy in bio-renewables turning biomass into consumer energy products building Fishcer-Tropsch reactors, fluidized bed gasifiers, and fixed bed syngas reactors.
Evan joined Cargill, the largest private food company in the world, in 2010; there he worked in corn and soy bean processing plants, implementing new production systems, improving production processes and managing production facilities. In 2014, Evan joined Deutsche Beverage Technology as a project engineer, designing and implementing sanitary brewing equipment. As the cannabis industry has grown over the last 4 years, Evan has implemented his background in large scale sanitary process optimization and design for developing cannabis extraction, evaporation, distillation and crystallization technologies at the industrial scale.

Herah is the mother to 15 year old twins that have Fragile X syndrome, the leading genetic cause of Autism. Herah has spent the last six years researching the treatment of cannabis with children that have rare diseases such as Fragile X syndrome. To better understand how the use of cannabis can treat and improve the quality of life for her children and others with seizure disorders and ASD. She discovered the need to create a consistent and reliable cannabis product line that parents felt was safe for children and adults with compromised immune systems. She has been able to share her knowledge with every dispensary in the state of Nevada as she has worked with Silver State Trading based out of Sparks, NV for the past two years and is currently the Nevada Sales Manager. Herah is an advocate and speaker regarding the use of cannabis in Autism and other developmental disabilities and rare diseases.

Dr. Paszko is an innovative, customer-centric leader with strong communication skills and the ability to collaborate well with both sales and technical teams. A strong leader with a commitment to driving growth in the rapidly evolving technology industry. Her unique career combines a Ph.D. in infectious disease and Microbiology with 20+ years of experience in defining and directing marketing and sales and business development strategies. This approach has helped customers to outperform competitors with best in class Laboratory Information Management Systems, Positive ID, and Automation Technology. Dr. Paszko's multicultural background provides a real-world understanding of the importance of sales leadership and relationship management to the bottom line.

Mr. Patel leads the strategic vision, financial health and global growth of PathogenDx, a Scottsdale, AZ based company which provides disruptive DNAbased pathogen testing technology and solutions for the cannabis, botanical, food and agricultural industries.
Previously, Mr. Patel spent over 25 years working with large public, small private and entrepreneurial companies in numerous fields from the life sciences, to biotechnology, to government services and the automotive industry. Milan served as COO/CFO of GMSbiotech. He also was CFO of 2020 Company, LLC, a leading premier professional services firm that delivered business and technology solutions to the government, in the areas of health, education and science.
Mr. Patel also worked at Intel Corporation in Sales & Marketing, Finance and Manufacturing. He has extensive experience in corporate finance, mergers and acquisitions, business strategy and planning, infrastructure and organizational development, and controls, compliance and audit.
For more information on PathogenDx's simple, powerful and inexpensive DNAbased pathogen testing, visit www.pathogendx.com.

Ezra Pryor has been in the cannabis industry for the past 6 years. He is Heidolph North America's Applied Markets Specialist and serves on the American Chemical Society's Cannabis Chemistry Subdivision as well as ASTM International's Committee D37 on Cannabis. Heidolph brings to the table more than 7 decades of experience providing premium equipment and expertise to highly regulated pharmaceutical and research industries. Now the new Heidolph Botanical Extraction (HBX) business unit is focused on providing unique solutions that are both efficient and compliant with cannabis industry regulations.

Dr. Roggen's latest project, Complex Biotech Discovery Ventures, a fundamental research laboratory and CRO of the cannabis industry. His research interests lie in the metabolite composition and behavior throughout the production cycle, SFE process optimization, and development of innovative therapeutic formulations. Dr. Roggen received his master in science degree from Imperial College, London, UK in 2008. He then pursued his graduate degree is organic chemistry at the Federal Institute of Technology in Zürich (ETHZ), where he received his PhD in 2012. He then was awarded an DAAD postdoctoral fellowship to pursue further training in physical organic chemistry at The Scripps Research Institute in La Jolla from 2013-2014. He then entered the cannabis industry, at first as laboratory director for Davinci Laboratories of California, an analytical laboratory from 2014 to 2016. In 2016 he moved into an executive position overseeing production, R&D and process optimization for OutCo, a cannabis manufacturer. Dr. Markus Roggen is also a trusted advisor and mentor for multiple startups, startup accelerators and organizations. Positions include advisory positions at Bloom Automation, a cannabis robotics company, Redfield Proctor, a waste management company, and former co-chair of the NCIA Scientific Advisory Committee.

Julie Taylor is the Founder and CEO of North Star Scientific Solutions, a consulting company specializing in setting up cannabis testing labs since 2016. Prior to entering the cannabis industry in 2014, Julie worked in the pharmaceutical industry with a focus on analytical instrumentation, bioanalytical analysis, compliance and drug metabolism research studies. Her experience from the pharmaceutical industry transferred seamlessly to the cannabis testing industry. North Star Scientific Solutions specializes in: lab design, laboratory standard operating procedures, analytical methods, compliance, ISO 17025 assistance, application assistance, project management and staffing solutions. She has experience working in the cannabis industry across numerous states and countries, which helps to easily navigate different regulatory requirements.
When Julie is not working, she is a Colorado girl. Her hobbies include paragliding, mountain biking, skiing, fly fishing and leather craft.

Marian has over 17 years of experience working as an analytical chemist supporting applications in the food and environmental, pharmaceutical and materials science industries. She has held several senior scientist positions developing quantitative analytical methods to meet regulatory requirements. Marian holds a Ph.D. in analytical chemistry from Cork Institute of Technology, Ireland. Currently, the focus of Marian's work is in the development of robust analytical methods to meet regulatory compliance in cannabis safety testing. She considers it an honour to work with other scientists to solve analytical problems using chromatography, sample preparation and mass spectrometry technologies.

Sponsored By

For information on becoming a sponsor or exhibitor, please click here.

Agilent (www.agilent.com) is a leader in life sciences, clinical research, diagnostics and applied chemical markets. With over 11,000 employees worldwide, the company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling
...
customers to gain the insights they seek. Agilent's expertise and trusted collaboration give them the highest confidence in our solutions.
Agilent focuses its expertise on six key markets, where we help our customers achieve their goals:
• Food: Agilent products can help ensure that our global food supply is free of contaminants-whether chemical, viral, bacterial or microbiological
• Environmental and Forensics: From pesticides to pharmaceutical residues to trace metals, Agilent provides fast, accurate and sensitive analytical methods for monitoring contaminants affecting quality of life
• Pharmaceutical: Agilent has one of the broadest solutions portfolios of any company serving the pharmaceutical industry
• Diagnostics: Agilent's reliable diagnostic products give doctors the information they need in the fight against cancer and other diseases
• Chemical and Energy: The world runs on energy, and energy companies need to locate, extract and refine fuels efficiently and cost-effectively
• Clinical Research: Most life sciences and clinical research is done at top-tier universities, with funding from governments around the world

Welcome to The Cannabis Reporter, an online media outlet, and syndicated radio show educating millions on the benefits of medical cannabis.

C.E. Credits

The speakers below have been approved for CME, CE, or CEU credits. To redeem your credits, locate the presentation you watched and click on the CME/CE/CEU buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here

Virtual poster sessions offer the opportunity to present data to a global audience via a PDF poster and video summary, and discuss results with interested colleagues through email. Posters should be submitted as a PowerPoint file. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. This content is not peer-reviewed. Submission is free.

All submitted abstracts will be reviewed and decisions regarding acceptance will be made as abstracts are received. You will be notified within one week of receipt about acceptance. Further details and registration materials will be provided at that time. You do not have to be present in order to have a poster displayed. Only those abstracts approved by LabRoots may display posters at this event.

If accepted, you will also have the opportunity to record a 3-5 minute summary video for each poster. LabRoots will work with each individual to create these videos. Video links and email contact information will be included on each poster displayed.

Kent Crowley, Pharm.D., is a board-certified Pharm.D. through the American Academy of Anti-Aging Medicine. He received his Doctor of Pharmacy from University of California, San Francisco and completed his residency with Kaiser Permanente in Los Angeles, CA. He completed his
...
Fellowship in Metabolic and Nutritional Medicine in 2011. During his 34 years in practice, he has worked in primary research at UCI, Dept. of Pediatrics, Division of Child Development, involved in the development of several drugs; holds two patents in neuropathic pain and a patent on a buccal delivery system incorporating cannabis.
Dr. Crowley currently is the Director of R&D at Silver State Trading in Sparks, NV, a 40,000 sq.ft. permitted Clean Green cannabis cultivation and production facility. He serves as the CMO for the Palliative Care Corporation in Huntington Beach, CA, working with patients & physicians incorporating cannabis in disease state treatment and symptoms management, whether as a primary treatment or complementary to traditional and/or other modalities. This same approach is practiced through Bud and Bloom in Santa Ana, CA as a clinic day each week for patients to come to a Best in Class dispensary and get good information/education on cannabis products/dosage forms/routes of administration and incorporate that into a functional medicine consult for personalized treatment goals.
Dr. Crowley is a member of the Society of Cannabis Clinicians and serves on the Research Subcommittee and a member of the International Cannabinoid Research Society.

Russell Cersosimo Jr. is the founder of Pittsburgh-based Miradati Technology, which is currently developing HIPAA-compliant, enterprise software that creates standardized data for medical cannabis research. Integrating both legacy and proprietary technologies, Miradati helps
...
facilitate this rapidly developing field of study, producing quantifiable data that more accurately measures patient outcomes, reduces prescribing errors and lowers patient costs.
Up until 2104, it's safe to say Cersosimo had, at best, an agnostic view of the medicinal benefits of the popular recreational drug. That would soon change after he was introduced to the family of Hannah Shuker, an 11 year-old girl with severe intractable epilepsy. Hannah instantly captured Cersosimo's heart and the desire to help save her life forever changed his.
Witnessing first hand how profoundly cannabis could improve Hannah's condition, Cersosimo made it his mission to help get such medicine into the hands of other patients and families, equally desperate for hope. These efforts led him in 2015 to found the Pennsylvania Medical Cannabis Society (PAMCS), the Commonwealth of Pennsylvania's largest organization for professionals, educators and leaders in the industry. It should come as no surprise that PAMCS' and Cersosimo's advocacy efforts were instrumental in 2016's successful legalization campaign.
Today, Cersosimo is committed to forging partnerships that improve the capture and analysis of medical cannabis data. Cersosimo is passionate about developing solutions that will shape the industry and help more patients like Hannah around the world. With that operating vision at its core, Cersosimo's Keystone Integrated Care, was recently awarded multiple licenses to operate medicinal dispensaries throughout southwestern Pennsylvania.
A serial entrepreneur as far back as his days studying Psychology at West Virginia University, Cersosimo founded Webbula, a data-centric technology company. As its CEO, Cersosimo generated high-profile clientele including Google, Yahoo, T-Mobile, Neustar, and Epsilon. Mr. Cersosimo has also served as CEO for marketing firm Optimal Reach Media. He currently sits on the Board of Directors of the Tourettes Syndrome Awareness Foundation.

Sebastien Cotte became actively involved in the field of medical marijuana in 2013 while seeking alternative treatments for his son Jagger's, rare terminal Mitochondrial disease. In 2014, with his wife Annett, they became medical refugees in Colorado to access cannabis oil for
...
Jagger. They lived in Colorado for 13 months before moving back to Georgia. Sebastien received a bachelor degree in international business from the University of Indianapolis and has over 15 years of business experience at several Fortune 500 companies. His areas of expertise include: human resources, training, process improvements, sales management, customer care, marketing, brand building, etc. Sebastien also completed a Medical Marijuana certification program offered by Americans for Safe Access and is in the process of finishing a few more industry certifications. He serves as an ambassador for the United Mitochondrial Disease Foundation and is one of the co-founder of Georgia's Hope, the leadership parent group that was successful in getting a Medical Cannabis law passed in Georgia. (HB1 Haleigh's Hope). Sebastien is the national business/education director and a board member for the Flowering Hope Foundation (a 501c no for profit that provides education and patient support for Haleigh's Hope-Cannatol products). He is also on the board of advisor of MDherb, a cannabis education website, the Georgia action group leader for Americans with Safe Access and the VP of the "Talk to the 6630507 hand" campaign which aim at de-scheduling cannabis.

James Eaves received his Ph.D. in Agricultural Economics from the University of California, Davis. Today, he is a management professor at Université Laval, where he is part of a research group that aims to find ways to increase the profitability of growing cannabis indoors and
...
in greenhouses. He is a regularly invited speaker at cannabis conferences across North America, writes for Canada's leading cannabis trade journal, and his award-winning research has been discussed in numerous media outlets, including The Washington Post, Newsweek, and the CBC.

Debra Kimless, M.D. graduated magna cum laude, Phi Beta Kappa from Muhlenberg College with a double major in Natural Sciences and Biology. She attended medical school at Rutgers, and residency at Temple University Hospital and is a boarded Anesthesiologist with a subspecialty
...
certification in Pain Medicine.

Catharine is a Senior Technical Applications Chemist at Waters Corporation in Milford, MA where she works closely with technical experts in chromatographic purification, supercritical fluid separation, and bio-botanical extraction. Catharine received undergraduate degrees in
...
Biological Science and Chemistry at the University of North Carolina at Chapel Hill and her Master's degree at Western Connecticut State University. She began her career in Biopharmaceutical Research and Development at a fast-paced, international contract research organization and drug development laboratory where she was responsible for the design of analytical methods used to characterize novel biological therapeutics formulated by key research organizations. Catharine later moved into large pharma where she dedicated over 15 years to the development of analytical methods and implementation of testing strategies for drug delivery devices and complex small molecule formulations while working in both the United States and Europe. She is most recently the author of "The Beginners Guide to Preparative Liquid Chromatography".

Jahan Marcu, Ph.D., is currently the Chief Science Officer at Americans for Safe Access (a medical cannabis advocacy non-profit) and Director of the Patient Focused Certification program, which is a health and safety oversight program that assesses regulatory compliance at
...
cannabis operations. He is co-founder and past-chairman of the CANN subdivision of the Chemical Health and Safety Division (DCHAS) of the American Chemical Society. His is also on the Board of Directors of the International Association for Cannabinoids as Medicine. He has a background in analytical chemistry and molecular pharmacology, he received his Ph.D. for contributions in characterizing the structure and function of the cannabinoid receptors.
He is an author of the American Herbal Pharmacopeia's Cannabis Monograph and serves on multiple expert government, trade association committees, scientific organizations including AHPA, ACS, AOCS, AOAC, ASA, IACM, and IMCPC. And is a court-qualified synthetic cannabinoid and cannabis expert. He has helped create medical cannabis educational training for clinicians and for workers in the medical cannabis industry, and has been invited to speak at many international conferences and universities, including the University of Leiden, Temple University School of Medicine, Princeton Hospital, and Yale University. Dr. Marcu is also a court qualified expert witness on cannabis and synthetic cannabinoids.

Dr. Paszko is an innovative, customer-centric leader with strong communication skills and the ability to collaborate well with both sales and technical teams. A strong leader with a commitment to driving growth in the rapidly evolving technology industry. Her unique career
...
combines a Ph.D. in infectious disease and Microbiology with 20+ years of experience in defining and directing marketing and sales and business development strategies. This approach has helped customers to outperform competitors with best in class Laboratory Information Management Systems, Positive ID, and Automation Technology. Dr. Paszko's multicultural background provides a real-world understanding of the importance of sales leadership and relationship management to the bottom line.

Continuing Education (CME/CE) Support

Please update your information

Certificate of Attendance

Thank you for choosing LabRoots. Please note that a Certificate of Attendance does NOT count towards Continuing Education Credits.
Please see the CE Credits tab if you are interested in Continuing Education Credits. Otherwise, click the button below to receive your Certificate of Attendance